Dr Michelle Henderson is a senior scientist at the Children’s Cancer Institute and joint manager of the Molecular Diagnostics Group.
She is excited about the potential of her work that stands to result in a more gentle and effective therapy for children at greatest risk.
Along with a team of colleagues and collaborators, Dr Henderson is investigating which sub-types of leukaemia are most likely to respond to a newly discovered drug. But it all relies on long-term funding.
“We have currently reached a ceiling where the chemotherapy options that work for most kids cannot be successfully used to cure the particularly aggressive cases.”